Vico Therapeutics BV

Please note: The information displayed on this page might be outdated.
Vico Therapeutics BV: Vico Therapeutics is a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare severe neurological disorders. Vico’s antisense oligonucleotide platform (AON) is focusing on different forms of Spinocerebellar Ataxia (SCA) and Huntington Disease (HD). Its early discovery RNA editing platform is directed towards RETT syndrome.

Vico was founded in 2019 by highly experienced entrepreneurs Luc Dochez and Josh Mandel-Brehm and seasoned scientists Dr. Judith van Deutekom and Dr. Gail Mandel with strong academic reputations and vast industry experience.
Based in...
J.H. Oortweg 21
Leiden, 2333

Company Participants at European Biotech Investor Days 2021

Gertjan Bartlema
Vico Therapeutics BV, Chief Business Officer
Gertjan Bartlema, most recently was the Executive Vice President Corporate Strategy & Business Development at Celularity Inc. in Warren, New Jersey. Previously he was the Vice President of information, Knowledge & Utilization at Celgene Corporation headquartered in Summit, New Jersey. Prior to this role, Gertjan held the positions of General Manager Middle East, Africa & Greece and Executive Director Marketing & Sales Excellence for Celgene EMEA, based in Switzerland. He previously was a member of Celgene’s Business Development team that acquired Gloucester Pharmaceuticals Inc. and Abraxis BioScience Inc. Mr. Bartlema started with Celgene in May 2006 in Business Planning EMEA based in Neuchatel, Switzerland. Prior to joining Celgene, he worked at Amgen where he started his career in Biotech in 1997 at their European headquarters, based in Lucerne, Switzerland. He joined their Corporate Financial Planning & Analysis group in 1999 based in Thousand Oaks, California. Mr. Bartlema holds a Masters in Economics from Maastricht University, The Netherlands and has a dual Dutch and Swiss citizenship.